Compare Affirm Holdings Inc (AFRM) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Affirm Holdings Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? Affirm Holdings Inc trades at $77.35 (market cap $25.69B), while Alnylam Pharmaceuticals, Inc. trades at $221.5 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Affirm Holdings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| AFRM | ALNY | |
|---|---|---|
Market Cap | $25.69B | $29.60B |
Sector | Financials | Health |
52-Week High | $92.18 | $491.22 |
52-Week Low | $42.53 | $205.48 |
Enterprise Value | $32.30B | $27.56B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Affirm Holdings Inc
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Read more on AFRM →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
